List of Excipients in Branded Drug AIRDUO RESPICLICK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Respiratory LLC	AIRDUO RESPICLICK	fluticasone propionate and salmeterol	59310-805	LACTOSE MONOHYDRATE

Last updated: July 30, 2026

AIRDUO RESPICLICK excipient strategy and commercial opportunities

Executive summary: AIRDUO RESPICLICK (fluticasone propionate/salmeterol) uses a dry-powder inhaler (DPI) architecture that narrows excipient choice to components that support powder dispersion, aerodynamic performance, and stability under low-humidity conditions. Commercial opportunities concentrate on (1) line extensions that maintain the same inhaler-platform powder engineering, (2) proprietary-sounding formulation routes that defend against generic “same-drug, different-excipient” design-around, and (3) development of combination-DPI “me-too plus” variants that preserve inhaler compatibility while improving dose uniformity, patient delivery, and lifecycle value through exclusivity stacking around formulation and device-adjacent IP.

---

What excipients are in AIRDUO RESPICLICK and how do they affect DPI performance?

Featured snippet answer: AIRDUO RESPICLICK is a DPI containing fluticasone propionate and salmeterol with excipients engineered to improve powder flow, mixing, and aerosolization from a multi-dose inhaler. In DPI products, the key excipient strategy is typically controlling moisture uptake and promoting consistent dispersion rather than dissolving a liquid formulation.

How DPI excipient strategy differs from pMDI or nebulized combinations

DPIs rely on the patient’s inhalation to deaggregate particles. Excipient choices therefore drive:

• Aerosolization efficiency (particle detachment and deaggregation)
• Dose uniformity across the dose counter range
• Flowability and blend stability during manufacturing and packaging
• Moisture sensitivity and stability in blister/foil or strip packaging

In this product category, excipient strategy is usually about:

• Mitigating hygroscopicity of the blend (to prevent caking and dose drift)
• Supporting segregation control between actives (critical in combination products)
• Ensuring reproducible emitted dose across pressure-driven inhalation variability

Commercial implication for an excipient platform

If a manufacturer can claim superior powder engineering tied to excipient composition and processing controls, it can:

• Improve real-world delivery (less “fine particle loss”)
• Differentiate clinically even when actives are unchanged
• Create licenseable formulation IP for new strengths, dosing regimens, or indications using the same inhaler platform

---

How should an excipient strategy be designed for fluticasone propionate/salmeterol dry powder inhalers?

Featured snippet answer: For fluticasone/salmeterol DPIs, the excipient strategy centers on controlling moisture, improving blend homogeneity, and ensuring consistent deaggregation under patient inhalation.

Key excipient functions typically targeted in combination DPI blends

1. Anti-caking and moisture barrier performance
   • Prevents moisture-driven aggregation that reduces respirable fraction.
2. Flow and mixing behavior
   • Ensures stable dose metering through fill mass variability.
3. Dispersion and deaggregation
   • Promotes reproducible detachment from carrier-like excipients and from each other.
4. Mitigation of electrostatic effects
   • Improves powder dispersion consistency in DPIs.
5. Compatibility with packaging
   • Excipient selection is intertwined with foil/aluminum laminate choice and desiccant strategy.

Formulation architecture: what matters commercially

For combination DPIs, excipient design must:

• Keep dose-to-dose uniformity stable across multi-dose containers
• Reduce inter-unit variability that can trigger post-launch reliability issues
• Enable scale-up reproducibility for lifecycle line extensions

This matters because competitive entrants often target “same actives, different formulation” to create an easier manufacturing pathway. A strong excipient strategy can raise the engineering burden and reduce the risk of dose delivery variability for the innovator and generics alike.

---

What patents protect AIRDUO RESPICLICK excipient and formulation choices?

Featured snippet answer: The strongest protective perimeter in combo DPI products usually sits in formulation patents covering composition ranges, excipient identity/type, particle engineering, and manufacturing/process parameters tied to emitted dose and stability.

Where formulation IP typically lands for combo DPI products

• Composition claims that specify excipient selection and ratio ranges
• Process claims tied to blending, milling, granulation, or mixing sequences
• Particle engineering claims controlling:
  • particle size distributions of actives in the blend
  • distribution of actives across excipient particles
• Stability claims that link excipient system to performance under stress

Why excipient IP is strategically important against generics

Even if a challenger matches active forms and device, they must also hit:

• emitted dose and fine particle metrics
• stability and dose uniformity across the shelf life
• aerosol performance under multiple patient flow scenarios

Excipient-centered patents give leverage in:

• settlement leverage during Paragraph IV disputes
• licensing terms for “design-around” formulations
• injunction risk if a product falls within claimed formulation ranges

---

When does AIRDUO RESPICLICK lose exclusivity and what timing windows matter for excipient-based line extensions?

Featured snippet answer: For combo inhaled products, exclusivity is driven by a mix of regulatory exclusivities (if any new NDA/BLA grant) and patent expirations that typically include formulation and device-adjacent IP. The “commercially relevant” window for excipient-based lifecycle moves is usually the period before the first material formulation patent expires.

How to think about timing for excipient strategy

• Early patent expirations: challengers can file and use design-arounds that target excipient changes to avoid composition claims.
• Late patent expirations: even if a competitor can file, they may still face formulation process and performance claims.
• Settlements: frequently structure authorized generic timing tied to patent carve-outs.

Business consequence for lifecycle design

A meaningful excipient formulation strategy can support:

• strength or dosing regimen switches that preserve device compatibility
• indication expansions without re-litigating the base formulation perimeter
• manufacturing modernization to reduce COGS while keeping performance within patent boundaries

---

What generic entry risks exist for AIRDUO RESPICLICK based on excipient design-around?

Featured snippet answer: The main generic risk is that challengers can avoid composition-range claims by using different excipient identities or ratios while still meeting regulatory equivalence. The counter-risk to the innovator is that generic entrants might successfully replicate DPI performance without using the claimed excipient system.

Where design-arounds succeed in DPI

• substituting excipient systems that produce similar emitted dose and fine particle fraction
• altering blending/process parameters while staying within approval equivalence criteria
• using alternative moisture-protection packaging that reduces reliance on excipient composition

Where design-arounds fail

• when performance is tightly coupled to claimed excipient composition and particle-engineering conditions
• when stability and dose-uniformity results are the key differentiator protected by IP
• when device compatibility is linked to powder characteristics that are also claimed

---

What Orange Book status applies to AIRDUO RESPICLICK and how does that affect excipient challenges?

Featured snippet answer: Orange Book listings control patent-driven challenge mechanics for NDA products. For DPI combination drugs, formulations and method-of-use patents listed in the Orange Book typically determine whether a Paragraph IV challenge targets excipients directly or uses equivalence data to argue non-infringement.

How Orange Book listings translate into excipient strategy

• If composition-of-matter patents are listed, challengers must design around excipient system claims or accept a later launch.
• If only use-related patents are listed, excipient substitution can be easier and the main risk moves to performance similarity rather than IP avoidance.
• If multiple layers are listed (composition + process + stability), excipient redesign becomes a high-effort, high-cost proposition.

(Orange Book listing details are required to produce a complete status map; without those specific listings, this section stays at the strategic level.)

---

How does AIRDUO RESPICLICK compare with competing fluticasone/salmeterol DPIs on formulation and excipient differentiation?

Featured snippet answer: Competitors in fluticasone/salmeterol inhalation typically differentiate through powder engineering, emitted-dose control, and moisture-handling strategies rather than through changes to the actives.

Competitive axes where excipients create measurable differentiation

• Consistency of fine particle fraction across doses
• Reduced delivered dose drift over shelf life
• Better aerosolization at lower inhalation flows
• Improved blend stability under manufacturing stress

Commercial opportunity from outperforming excipient-driven constraints

A competitor that can show:

• higher delivered dose variability improvement
• lower patient technique sensitivity
• stability under higher humidity excursions
  can convert excipient and process improvements into market share, formulary wins, or payer preference.

For the incumbent, excipient IP can:

• strengthen exclusivity around performance outcomes
• support licensing and partnership models for new strengths
• defend against “authorized generic” strategies that rely on design-around formulations

---

What formulation and manufacturing IP barriers arise from excipient choices for AIRDUO RESPICLICK?

Featured snippet answer: The highest barriers come from excipient system claims that are tied to manufacturing process controls and performance metrics, especially where stability and fine particle aerosolization are correlated to the excipient blend.

Process controls that commonly increase IP and operational barriers

• blending order and residence time
• milling/particle size conditioning of actives in the blend
• humidity-controlled processing steps
• packaging moisture barrier configuration tied to excipient behavior

Lifecycle implications

Excipient choices can be locked into:

• validated manufacturing pathways
• stability study plans and comparability packages
• device-powder interface calibration (metering and deaggregation)

That raises switch cost and can support:

• premium pricing for performance
• defensible line extensions using the same platform

---

What commercial opportunities exist for AIRDUO RESPICLICK excipient strategy across lifecycle expansion?

Featured snippet answer: The most actionable opportunities are excipient-led improvements that preserve DPI platform compatibility, support new strengths or dosing regimens, and defend against generic performance and stability equivalence.

1) Line extension using same inhaler platform

• New strengths or tailored dosing regimens that leverage a platform DPI feed system
• Excipient system optimization that improves:
  • dose uniformity at low or high mass fills
  • shelf-life robustness under real-world humidity

Commercial payoff: lower device revalidation cost, faster time to market.

2) Indication expansion powered by stability and dose delivery

If excipient and powder engineering reduce variability, that can support:

• stronger patient adherence claims
• reduced “rescue” medication usage in outcomes (where supported by clinical evidence)

Commercial payoff: payer and provider uptake based on reliability.

3) Proprietary performance claims that can be licensed

Excipient and processing tied to emitted dose and fine particle outcomes is licenseable to:

• contract manufacturers that need a defensible formulation package
• regional partners for authorized manufacturing
• platform deals for next-generation DPIs

Commercial payoff: monetization without re-running full base clinical programs.

4) Anti-counterfeit packaging and moisture control as a value layer

Even when excipients are unchanged, packaging choices that protect moisture uptake can be marketed and can reduce returns or complaint rates.

Commercial payoff: improved pharmacovigilance and reduced field failures.

---

Key commercial scenarios for investors and business development

A. Defense scenario: strengthen formulation perimeter

• Focus resources on maintaining powder engineering controls that are tied to excipient and stability claims.
• Use formulation change control to minimize drift that can reduce the legal defensibility of claimed powder characteristics.

B. Offense scenario: out-pace generic design-around

• File continuation applications where permissible to extend formulation/process protection around excipient-related performance.
• Build evidence packages that show performance superiority is dependent on the excipient system, not just particle size or device.

C. Deal scenario: license the excipient platform

• License to partners for inhaled combination DPIs that require similar moisture and deaggregation performance.
• Structure agreements around field-of-use and manufacturing method controls.

---

Key Takeaways

• DPI excipient strategy is primarily about moisture handling, powder flow and mixing stability, and deaggregation performance under patient inhalation.
• AIRDUO RESPICLICK’s commercial differentiation depends on powder engineering tied to excipient system selection and validated manufacturing controls.
• The most credible commercial opportunities are lifecycle line extensions and platform-based partnerships that preserve inhaler compatibility while improving delivered dose consistency and stability.
• Generic and biosimilar-style competitive pressure is best mitigated when formulation/process claims link excipient composition to measurable performance outcomes (emitted dose, fine particle fraction, dose uniformity, shelf-life stability).

---

FAQs

1. How do excipients influence emitted dose and fine particle fraction in dry powder inhalers?
2. Which formulation parameters are typically most difficult for generic entrants to replicate in fluticasone/salmeterol DPIs?
3. How does moisture barrier packaging interact with excipient choice in DPI stability?
4. What excipient-centered design-arounds most often reduce infringement risk in combination DPI patents?
5. How can a lifecycle strategy use excipient and process improvements without changing core device architecture?

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. Guidance for Industry: Bioequivalence Studies for Nasal Aerosols and Inhalation. FDA.
3. U.S. Food and Drug Administration. Guidance for Industry: Potency Tests for Drug Products. FDA.
4. European Medicines Agency. Guideline on the Investigation of Bioequivalence. EMA.